- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- COVER PAGE
- COMMITTEE TO REVIEW THE FIALURIDINE (FIAU/FIAC) CLINICAL TRIALS
- Preface
- Contents
- Executive Summary
- 1 Introduction
- 2 Clinical Trials
- 3 Hepatitis B and Other Viral Diseases
- 4 Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center
- 5 Oclassen Clinical Trial R89-001-01
- 6 Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031)
- 7 Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213)
- 8 Eli Lilly Trial H3X-MC-PPPA
- 9 Eli Lilly Trial H3X-MC-PPPG
- 10 Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031)
- 11 Summary of Patient Interviews
- 12 Overall Assessment of the Trials
- 13 Recent Studies of FIAU Toxicity
- 14 Review of the FDA Task Force Report "Fialuridine: Hepatic and Pancreatic Toxicity
- 15 Review Of "Report To The Advisory Committee To The Director, National Institutes Of Health"
- 16 FDA-Proposed Changes To The Code Of Federal Regulations
- 17 Ancillary Issues Raised During The Period Following The H3x-Mc-Pppc Trial
- 18 Conclusions and Recommendations
- Appendixes
- Glossary